At the Neurosurgery & Spine Group (NSG), based in Los Angeles, neurosurgeons Dr. Jared Ament and Dr. Amir Vokshoor have ...

A new study reveals that neural stem cell grafts can generate new myelin in the central nervous system, offering hope for ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

CT scans showed mass in thoracic spine 6–8, vertebral fracture, and left pleural effusion. This patient was diagnosed as IgA-λ MM at the DS IIIA stage (or ISS III, R-ISS III stage with EMD), ...

Multiple sclerosis (MS) patients often present with lesions in spinal cord magnetic resonance (MR) volumes. However, accurately detecting these lesions is challenging and prone to inter-and ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...